ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0765

RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives

Guy Katz1, Melissa Briones2, Nina Couette3, Meridith Balbach4, Sabahat Usmani5, Lauren He6, Michael Macklin6, Iman Qaiser7, John Kellogg8, Courtney Bair8, Benjamin Lueck8, Akrithi Garren9, Matthew Sparks8, Lisa Criscione-Schreiber8 and David Leverenz8, 1Massachusetts General Hospital, Boston, MA, 2Loyola University, Maywood, IL, 3Genesis Healthcare System, Columbus, OH, 4Vanderbilt University Medical Center, Nashville, TN, 5Weiss Memorial Hospital, Chicago, IL, 6University of Chicago, Chicago, IL, 7Louisiana State University, Shreveport, LA, 8Duke University School of Medicine, Durham, NC, 9MedStar/Georgetown Washington Hospital Center, Silver Spring, MD

Meeting: ACR Convergence 2023

Keywords: education, medical

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Professional Education

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: RheumMadness is an online tournament of rheumatology concepts that has been shown to engage learners using the Community of Inquiry (CoI) framework. theMednet is another online educational platform in which physician users submit clinical questions that are answered by experts in the field in an interactive question and answer forum. We sought to evaluate the educational impact of integrating content and engagement between these two independent learning platforms.

Methods: The 2023 RheumMadness tournament consisted of 22 teams of competing concepts that were presented as scouting reports written by trainees and rheumatologists. On the day that scouting reports were published, 7 clinically-focused questions relating to specific RheumMadness teams (6 curated by theMednet team, 1 user-submitted) were posted on theMednet along with expert responses. Leadership teams from both RheumMadness and theMednet publicized updates about each other’s initiatives on their respective platforms. At the conclusion of the tournament, all participants, excluding leadership team members, were invited to complete a voluntary survey that assessed engagement in RheumMadness and theMednet as well as educational impact using the CoI framework. Surveys used Likert scores (1=very dissatisfied/strongly disagree, 5=very satisfied/strongly agree). Engagement in RheumMadness content on theMednet was examined and compared to that of its 5 most recent comparable educational programs. Statistical analyses were performed using Chi-square tests and unpaired T tests as appropriate.

Results: RheumMadness-related questions posted on theMednet and associated engagement are shown in Table 1; views per question ranged from 244 to 627, and number of poll voters per question from 53 to 80. When compared with the 5 most recent comparable educational programs on theMednet (Table 2), RheumMadness questions reached more users and institutions, and RheumMadness questions had significantly more views than questions from other educational programs (mean 459 vs. 249 views/question, respectively). Among RheumMadness participants, demographics and engagement with other RheumMadness curricular elements were similar between participants who engaged with theMednet content (n=24) and non-engagers (n=34), but CoI engagement was significantly higher in the overall cognitive presence and 3 of its components as well as the overall social presence among theMednet engagers (Table 3). Participants who engaged with theMednet Q&A reported that it contributed positively to the educational experience of RheumMadness (mean Likert score 4.25).

Conclusion: Establishing a collaboration between RheumMadness and theMednet strengthened learning in both programs. In addition to an effect of the collaboration, engagement with RheumMadness-related questions compared with previous educational programs on theMednet may have also been enhanced by the growing overall number of users over time and more varied nature of the topics presented in RheumMadness compared with previous programs. Collaborations between educational programs should be encouraged, as this may allow programs to reach broader audiences and accomplish more effective learning.

Supporting image 1

Table 1. Questions associated with RheumMadness teams on theMednet. DMARD: disease-modifying antirheumatic drug; ANA: antinuclear antibody; ANCA: antineutrophil cytoplasmic antibody; ULT: urate-lowering therapy; SLE: systemic lupus erythematosus; HCQ: hydroxychloroquine; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire; CPPD: calcium pyrophosphate deposition disease; NSAIDs: nonsteroidal anti-inflammatory drugs; MSU: monosodium urate.

Supporting image 2

Table 2. Engagement with RheumMadness questions compared with the five other most recent educational programs on theMednet. *Values for five educational programs combined and reported as mean (SD) unless noted otherwise. Other educational programs were journal clubs consisting of questions relating to recent landmark publications with answers from manuscript authors and other experts.

Supporting image 3

Table 3. Educational impact of RheumMadness in theMednet engagers and non-engagers. All values reported as mean (SD) Likert scores (1=very dissatisfied/strongly disagree, 5=very satisfied/strongly agree) unless noted otherwise.


Disclosures: G. Katz: None; M. Briones: theMednet.org, 3, 11; N. Couette: None; M. Balbach: None; S. Usmani: None; L. He: None; M. Macklin: None; I. Qaiser: None; J. Kellogg: None; C. Bair: None; B. Lueck: None; A. Garren: None; M. Sparks: None; L. Criscione-Schreiber: GlaxoSmithKlein(GSK), 5, UCB, 5; D. Leverenz: Pfizer, 5, Rheumatology Research Foundation, 5, Sanofi, 2.

To cite this abstract in AMA style:

Katz G, Briones M, Couette N, Balbach M, Usmani S, He L, Macklin M, Qaiser I, Kellogg J, Bair C, Lueck B, Garren A, Sparks M, Criscione-Schreiber L, Leverenz D. RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/rheummadness-and-themednet-the-impact-of-a-collaboration-between-independent-educational-initiatives/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheummadness-and-themednet-the-impact-of-a-collaboration-between-independent-educational-initiatives/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology